Encompass Health shares are trading lower after the company reported Q2 financial results. Also, Barclays maintained an Overweight rating on the stock but lowered its price target from $113 to $109.
Portfolio Pulse from Benzinga Newsdesk
Encompass Health shares are trading lower following the release of their Q2 financial results. Barclays has maintained an Overweight rating on the stock but has lowered its price target from $113 to $109.
August 06, 2024 | 5:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Encompass Health shares are trading lower after the company reported Q2 financial results. Barclays maintained an Overweight rating on the stock but lowered its price target from $113 to $109.
The lower trading of Encompass Health shares is directly tied to the Q2 financial results, which likely did not meet market expectations. Additionally, Barclays lowering its price target, despite maintaining an Overweight rating, suggests a cautious outlook, contributing to the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100